Bio-Rad and CCRM Nordic partner to accelerate advanced therapies

Bio-Rad and CCRM Nordic partner to accelerate advanced therapies 

CCRM Nordic, a leading organization dedicated to advancing research, development and commercialization of advanced therapy medicinal products (ATMPs), today announced it has entered into an Industrial Partnership Agreement with Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics. 

By combining Bio-Rad’s expertise in digital PCR and assay development with CCRM Nordic’s know-how and lab infrastructure, the partnership aims to accelerate the translation and commercialization of ATMPs across the Nordics and Europe. The collaboration utilizes and extends CCRM Nordic’s collaborative model and ultimately enables patients to benefit sooner from transformative new treatments. 

“At Bio-Rad, we are proud to support the advancement of cell and gene therapies through precise analytical technologies. This collaboration with CCRM Nordic reflects our commitment to empowering researchers and developers with robust tools that accelerate innovation and uphold quality across the ATMP value chain,” said Reg Chopra, Field Marketing Director, EMEA, Bio-Rad. 

“The future of advanced therapies depends on cutting-edge science, robust analytics and reliable processes for clinical translation. By joining forces with Bio-Rad, we are equipping ATMP teams with additional digital PCR power and well-developed analytical strategies. For patients, that means new hope delivered sooner,” said Fredrik Wessberg, CEO, CCRM Nordic.  

As part of the agreement, Bio-Rad also becomes a member of CCRM Nordic’s industry consortium, a collaborative network of innovators and industry leaders including AstraZeneca, Cytiva, and others—each contributing unique strengths to accelerate the development of CCRM Nordic and ATMP development. This partnership will further enhance CCRM Nordic’s ability to provide end-to-end support, from CMC strategy and scalable GMP manufacturing processes to commercialization guidance. 

Media contact:
Fredrik Wessberg
CEO, CCRM Nordic
fredrik.wessberg@ccrmnordic.se
+46 722 296905

About CCRM Nordic

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs. 
Learn more about CCRM Nordic: ccrmnordic.se 

About Bio-Rad 

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com. 

Bio-Rad Forward-Looking Statements   

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our collaboration with CCRM Nordic, our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.